Deepening their analysis from a Law360 article on Pay for Delay (“PFD”) deals in brand name pharmaceuticals, Atanu Saha and Yong Xu examine possible revenue generation for brands in a paper for the Journal of Industry, Competition and Trade.

The objective of this paper is to develop an analytical and estimation framework to empirically quantify a brand drug’s incremental revenue from delayed generic entry PFD deal. The paper’s dataset comprises 78 branded drugs and monthly data from January 2009 through March 2020. Consistent with the predictions of the analytical model, we find that relative to non-PFDs, PFD drugs have significantly higher revenue growth rates prior to generic entry. For the 13 PFD drugs in our sample, we estimate that the brands’ total incremental revenue from delaying generic entry ranges between $17.6 billion and $22.7 billion. We also show that delaying generic entry by a single year generates more than four times the brand’s annual revenue.

Click here to access the full paper.

Posted In:

About the Authors


Yong Xu

Dr. Yong Xu, a Managing Director with StoneTurn, brings over 20 years of experience in the application of economics, finance, and statistics to complex business issues. He has provided expert […]

Read Bio
Atanu Saha-HS

Atanu Saha

Atanu Saha, a Partner with StoneTurn, has over 25 years of experience in the application of economics and finance to complex business issues. He has served as an expert witness […]

Read Bio